Antibody Name/Symbol |
Antibody Description |
Clones/Alternative Names |
Chapters |
β-catenin |
beta catenin; involved in regulation of cell adhesion and in signal transduction through Wnt pathway |
B-catenin, CLONE 14, E-5, RB-9035Po, 17C2, 5H10 |
Fibromatosis; Granular Cell Tumor; Medullary Carcinoma; Nodular Fasciitis; Phyllodes Tumor; Tubulolobular Carcinoma; |
β-catenin cytoplasm |
|
B-caten-cyt |
Granular Cell Tumor Basal-like Carcinomas |
1A6 |
progesterone receptor protein |
PR, 10A9, PGR-1A6, KD68, PGR-ICA, PRP-P, PRI, 1A6, 1AR, HPRA3, PGR-636, 636, PR88, NCL-PGR |
Hormone Receptors (ER/PR) |
1D5 |
estrogen receptor protein |
1D5, 6F11, SP1, 15D, H222, TE111, ERP, ER1D5, NCLER611, NCL-ER-LH2, PGP-1A6 |
Hormone Receptors (ER/PR) |
34bE12 |
cytokeratin, high molecular weight (34bE12- CK 1, 5, 10, 14) |
MA-903, CK903 |
Basal-like Carcinomas; Lobular Carcinoma In Situ; |
3B5 |
v-erb-b2 erythroblastic leukemia viral gene protein, human epidermal growth factor receptor 2 |
Her2/neu, NEU, Her2, NCL-CBE1, 10A7, 9G6.10, SP3, 4B5, P185, 9G6.20, A0485, C-ERBB-2, CB11, ERBB-2, 3B5, TAB250, HERCEPTEST, E2-4001, HER-2_NEU |
HER2 |
4B5 |
v-erb-b2 erythroblastic leukemia viral gene protein, human epidermal growth factor receptor 2 |
Her2/neu, NEU, Her2, NCL-CBE1, 10A7, 9G6.10, SP3, 3B5, P185, 9G6.20, A0485, C-ERBB-2, CB11, ERBB-2, 3B5, TAB250, HERCEPTEST, E2-4001, HER-2_NEU |
HER2 |
6F11 |
estrogen receptor protein |
1D5, SP1, 15D, H222, TE111, ERP, ER1D5, NCLER611, NCL-ER-LH2, PGP-1A6 |
Hormone Receptors (ER/PR) |
Actin-sm |
smooth muscle actin |
SMA, ASM-1, CGA7, IA4, HUC-1 |
Anatomic Structure and Lifecycle Changes; Ductal Carcinoma In Situ with Microinvasion; Ductal Carcinoma In Situ; Encapsulated Papillary Carcinoma; Hemangiomas; Invasive Papillary Carcinoma; Myofibroblastoma; Nodular Fasciitis; Papilloma, Large Duct and Small Duct Sclerosing Adenosis; Tubular/Cribriform Carcinoma |
AE1/AE3 |
AE1/AE3; mixture of 2 anticytokeratin clones that detect a variety of both high-and low- molecular weight cytokeratins |
|
Invasive Lobular Carcinoma; Collagenous Spherulosis; Secretory Carcinoma; Neoadjuvant Therapy; Metaplastic Carcinoma; Lymph Node Metastases; Myofibroblastoma; HER2 |
ALK1 |
anaplastic lymphoma kinase-1 |
5A4, ALK, ALKC |
Iatrogenic Changes |
Androgen receptor |
|
AR441, F39.4.1, AR-N20, ANDROGEN RE, AR27 |
Invasive Apocrine Carcinoma; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Gynecomastia; HER2; Lobular Carcinoma In Situ; Metastases to the Breast; Myofibroblastoma; Myofibroblastoma; Nonproliferative Changes; |
Aromatase |
key enzyme in the byosynthesis of estrogen |
|
Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay; Expression Profiling, Protein; Gynecomastia; Hormone Receptors (ER/PR); Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Locally Recurrent Carcinoma |
Bcl-2 |
B-cell lymphoma 2; suppresses apoptosis in a variety of cell systems |
ONCL2, BCL2/100/D5, 124, 124.3 |
Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Myofibroblastoma |
Bombesin |
tumor marker for small cell carcinoma of the lung |
|
Neuroendocrine/Small Cell Carcinoma |
BRCA1 |
breast and ovarian cancer susceptibility protein 1; DNA repair protein |
MS110 |
Basal-like Carcinomas; Diabetic Mastopathy/Lymphocytic Mastopathy; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Expression Profiling, mRNA; HER2 Positive Carcinoma; Hereditary Cancer; Hormone Receptors (ER/PR); Lobular Carcinoma In Situ; Lymphoma; Mastectomies; Medullary Carcinoma; Risk Factors for Developing Breast Carcinoma |
BRCA2 |
breast and ovarian cancer susceptibility protein 2; protein involved in chromosome repair |
3E6 |
Gynecomastia; HER2 Positive Carcinoma Hereditary Cancer; Hormone Receptors (ER/PR); Lobular Carcinoma In Situ; Mastectomies; Medullary Carcinoma; Risk Factors for Developing Breast Carcinoma |
Calcitonin |
polypeptide hormone produced by parafollicular cells (C cells) of the thyroid |
CALBINDIN28 |
Neuroendocrine/Small Cell Carcinoma |
Caldesmon |
actin interacting and calmodulin binding protein found in smooth muscle and other cell types |
|
Sarcomas |
Calponin |
thin filament-associated protein that is implicated in regulation and modulation of smooth muscle contraction |
N3, 26A11, CALP, CNN1, SMCC, Sm Calp |
Adenoid Cystic Carcinoma; Anatomic Structure and Lifecycle Changes; Invasive Apocrine Carcinoma; Ductal Carcinoma In Situ with Microinvasion; Ductal Carcinoma In Situ; Fibromatosis; Hamartoma (Fibroadenolipoma); Nipple Adenoma; Nodular Fasciitis; Papilloma, Large Duct and Small Duct; Radial Sclerosing Lesion/Radial Scar Sclerosing Adenosis |
Calretinin |
29 kDa calcium binding protein that is expressed in central and peripheral nervous system and in many normal and pathological tissues |
DAK-CALRET, 5A5, CAL 3F5, DC8, AB149 |
Granular Cell Tumor |
Carcinoembryonic antigen, monoclonal |
|
CEA-M, mCEA, CEA-B18, CEA-D14, CEAGOLD 1, T84.6, CEA-GOLD 2, CEA 11, CEA-GOLD 3, CEA 27, CEAGOLD 4, CEA 41, CEA-GOLD 5, T84.1, CEA-M, A5B7, CEJ065, IL-7, T84.66, TF3H8-1, 0062, D14, alpha-7, PARLAM 1, ZC23, CEM010, A115, COL-1, AF4, 12.140.10, 11-7, M773, CEA-M431_31, CEJO65 |
Apocrine Carcinoma |
Carcinoembryonic antigen, polyclonal |
|
CEA-P |
Apocrine Carcinoma |
Cathepsin-D |
lysosomal aspartic protease overexpressed and hyper-secreted by epithelial breast cancer cells |
|
Microglandular Adenosis |
CB11 |
HER2/neu |
NCL-CBE1, 10A7, 9G6.10, SP3, 4B5, P185, 9G6.20, A0485, C-ERBB-2, ERBB-2, 3B5, TAB250, HERCEPTEST, E2-4001, HER-2_NEU |
HER2 |
CD1a |
T-cell surface glycoprotein |
JPM30, CD1A, O10, NA1/34 |
Fat Necrosis |
CD2 |
T-cell surface antigen, LFA2 |
271, MT910, AB75, LFA-2 |
Expression Profiling, mRNA; Histologic Grade; |
CD3 |
T-cell receptor |
F7238, A0452, CD3-P, CD3-M, SP7, PS1 |
Implant Pathology |
CD4 |
T-cell surface glycoprotein, L3T4 |
IF6, 1290, 4B12, CD4, 1F6, CD04 |
Diabetic Mastopathy/Lymphocytic Mastopathy |
CD10 |
neutral endopeptidase |
CALLA, neprilysin, NEP |
Anatomic Structure and Lifecycle Changes; Lipoma and Angiolipoma; Metaplastic Carcinoma |
CD20 |
membrane spanning 4 domains of B lymphocytes |
FB1, B1, L26, MS4A1 |
Diabetic Mastopathy/Lymphocytic Mastopathy; Lymphoma |
CD30 |
tumor necrosis factor SF8 |
BER-H2, KI-1, TNFRSF8 |
Implant Pathology; Lymphoma |
CD31 |
platelet endothelial cell adhesion molecule |
JC/70, JC/70A, PECAM-1 |
Angiosarcoma; Atypical Vascular Lesions of Skin; Ductal Carcinoma In Situ; Hemangiomas; Inflammatory Carcinoma; Lymph-Vascular Invasion; Pseudoangiomatous Stromal Hyperplasia |
CD34 |
hematopoietic progenitor cell antigen |
MY10, IOM34, QBEND10, 8G12, 1309, HPCA-1, NU-4A1, TUK4, clone 581, BI-3c5 |
Anatomic Structure and Lifecycle Changes; Angiosarcoma; Atypical Vascular Lesions of Skin; Diabetic Mastopathy/Lymphocytic Mastopathy; Fibroadenoma; Fibromatosis; Hemangiomas; Lipoma and Angiolipoma; Lymph-Vascular Invasion; Metaplastic Carcinoma; Myofibroblastoma; Nodular Fasciitis; Phyllodes Tumor; Pseudoangiomatous Stromal Hyperplasia; |
CD43 |
major sialoglycoprotein on surface of human T lymphocytes, monocytes, granulocytes, and some B lymphocytes |
LEU-22, DF-T1, L60, MT1, sialophorin, leukosialin, SPN |
Implant Pathology |
CD45 |
leukocyte common antigen |
LCA, PD7/26, 1.22/4.14, T29/33, RP2/18, PD7, 2D1, 2B11+PD7/26 |
Circulating Tumor Cells |
CD56 |
NCAM (neutral cellular adhesion molecule) |
MAB735, ERIC-1, 25-KD11, 123C3, 24- MB2, BC56C04, 1B6, 14- MAB735, NCCLU- 243, MOC-1, NCAM |
Mucinous (Colloid) Carcinoma |
CD68 |
cytoplasmic granule protein of monocytes, macrophages |
PG-M1, KP-1, LN5 |
Expression Profiling, Oncotype DX Assay; Fat Necrosis; Granular Cell Tumor; Nodular Fasciitis |
CD117 |
C-kit; tyrosine protein kinase activity |
C-19 (C-KIT), 104D2, 2E4, C-KIT, A4502, H300, CMA-767 |
Adenoid Cystic Carcinoma; Basal-like Carcinomas; Phyllodes Tumor; Secretory Carcinoma |
CDC2 |
cell division cycle 2 kinase |
|
Histologic Grade |
CDH1 |
epithelial calcium dependent adhesion molecule |
36B5, ECH-6, ECCD-2, 5H9, NCH 38, CLONE 36, 4A2 C7, E9, 67A4, HECD-1, SC-8426 |
Hereditary Cancer; Invasive Lobular Carcinoma Variants; Invasive Lobular Carcinoma; Lobular Carcinoma In Situ |
CDX-2 |
caudal-type homeobox transcription factor 2 |
AMT28, 7C7/D4, CDX-2-88 |
Invasive Lobular Carcinoma; Metastases to the Breast |
CEA-M |
carcinoembryonic antigen, monoclonal |
mCEA, CEA-B18, CEA-D14, CEAGOLD 1, T84.6, CEA-GOLD 2, CEA 11, CEA-GOLD 3, CEA 27, CEAGOLD 4, CEA 41, CEAGOLD 5, T84.1, CEA-M, A5B7, CEJ065, IL-7, T84.66, TF3H8-1, 0062, D14, alpha-7, PARLAM 1, ZC23, CEM010, A115, COL-1, AF4, 12.140.10, 11-7, M773, CEA-M431_31, CEJO65 |
Expression Profiling, Protein |
CEA-P |
carcinoembryonic antigen, polyclonal |
|
Ductal Carcinoma In Situ, Paget Disease |
Chromogranin-A |
pituitary secretory protein 1 |
PHE-5, PHE5, E001, DAK-A3 |
Neuroendocrine/Small Cell Carcinoma |
CK5 |
cytokeratin 5 |
CK 05, XM26, RCK103, 34BEH12 |
Invasive Apocrine Carcinoma Expression Profiling, mRNA; Expression Profiling, Protein; HER2 Positive Carcinoma |
CK5/6 |
cytokeratin 5/6 |
CK 05_06, D5/16 B4 |
Anatomic Structure and Lifecycle Changes; Invasive Apocrine Carcinoma; Basal-like Carcinomas; Ductal Carcinoma In Situ, Paget Disease; Epithelial Hyperplasia; Expression Profiling, mRNA; Expression Profiling, Protein; Hamartoma (Fibroadenolipoma); HER2 Positive Carcinoma; Hereditary Cancer; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Lobular Carcinoma In Situ; Medullary Carcinoma; Metaplastic Carcinoma; Nipple Adenoma; Papilloma, Large Duct and Small Duct; Risk Factors for Developing Breast Carcinoma; Sclerosing Adenosis; Tubular/Cribriform Carcinoma |
CK7 |
cytokeratin 7 |
CK 7, K72.7, KS7.18, OVTL 12/30, LDS-68, CK 07 |
Anatomic Structure and Lifecycle Changes; Ductal Carcinoma In Situ, Paget Disease; Neuroendocrine/Small Cell Carcinoma |
CK8 |
cytokeratin 8 |
K8.8, 4.1.18, TS1, C-51, M20, CK 08, 35BH11, MA-902 |
Anatomic Structure and Lifecycle Changes; Atypical Ductal Hyperplasia Medullary Carcinoma; |
CK14 |
cytokeratin 14, high molecular weight cytokeratin |
LL002 |
Expression Profiling, Protein; Fibromatosis; Medullary Carcinoma; Metaplastic Carcinoma |
CK17 |
cytokeratin 17 |
E3 |
Expression Profiling, Protein |
CK18 |
cytokeratin 18 |
M9, DC-10, CY-90, KS18.04 |
Anatomic Structure and Lifecycle Changes; Expression Profiling, Protein; Lobular Carcinoma In Situ; Medullary Carcinoma; Papilloma, Large Duct and Small Duct; Risk Factors for Developing Breast Carcinoma |
CK19 |
cytokeratin 19, low molecular weight cytokeratin |
BA17, RCK108, LP2K, B170, A53-BA2, KS19.1, 170.2.14 |
Circulating Tumor Cells |
CK20 |
cytokeratin 20, low molecular weight cytokeratin |
KS20.8 |
Ductal Carcinoma In Situ, Paget Disease; Invasive Micropapillary Carcinoma |
CK-HMW-NOS |
cytokeratin, high molecular weight, not otherwise specified |
keratin-HMW |
Atypical Ductal Hyperplasia; Ductal Carcinoma In Situ |
C-Kit |
tyrosine protein kinase activity |
C-19 (C-KIT), 104D2, 2E4, CD117, A4502, H300, CMA-767 |
Adenoid Cystic Carcinoma; Basal-like Carcinomas |
CK-PAN |
cytokeratin-pan (AE1/AE3/LP34); cocktail of high and low molecular weight cytokeratins |
keratin pan, MAK-6, K576, LU-5, KL-1, KC-8, MNF 116, pankeratin, pancytokeratin |
Core Needle Biopsies; Ductal Carcinoma In Situ with Microinvasion; Ductal Carcinoma In Situ, Paget Disease; Fibromatosis; Granular Cell Tumor; Iatrogenic Changes; Invasive Lobular Carcinoma; Lymph Node Metastases; Metaplastic Carcinoma; Myofibroblastoma; Phyllodes Tumor |
Collagen IV |
major constituent of the basement membranes along with laminins, proteoglycans, and enactins |
CIV22, COL4A [1-5], collagen α-1(IV) chain |
Ductal Carcinoma In Situ with Microinvasion; Microglandular Adenosis; |
CTSL2 |
|
Cathespin L |
Expression Profiling, Oncotype DX Assay |
Cytokeratin |
|
|
Adenoid Cystic Carcinoma; Anatomic Structure and Lifecycle Changes; Angiosarcoma; Invasive Apocrine Carcinoma; Atypical Ductal Hyperplasia; Atypical Lobular Hyperplasia; Basal-like Carcinomas; Circulating Tumor Cells; Collagenous Spherulosis; Ductal Carcinoma In Situ with Microinvasion; Ductal Carcinoma In Situ, Paget Disease; Ductal Carcinoma In Situ; Encapsulated Papillary Carcinoma; Epithelial Hyperplasia; Expression Profiling, mRNA; Expression Profiling, Protein; Fibromatosis; Granular Cell Tumor; Gynecomastia; HER2 Positive Carcinoma; HER2; Hereditary Cancer; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Lobular Carcinoma Variants Invasive Lobular Carcinoma; Invasive Papillary Carcinoma; Lobular Carcinoma In Situ; Locally Recurrent Carcinoma; Lymph Node Metastases; Medullary Carcinoma; Metaplastic Carcinoma; Metastases to the Breast; Microglandular Adenosis; Myofibroblastoma; Neoadjuvant Therapy; Papilloma, Large Duct and Small Duct; Radial Sclerosing Lesion/Radial Scar; Risk Factors for Developing Breast Carcinoma; Sarcomas; Sclerosing Adenosis; Secretory Carcinoma |
Cytokeratin 1 |
|
CK1, CK 01, 34BB4 |
Basal-like Carcinomas Circulating Tumor Cells; Ductal Carcinoma In Situ with Microinvasion; Fibromatosis; Hereditary Cancer; Secretory Carcinoma; |
Cytokeratin 4 |
|
215B8, 6B10 |
Basal-like Carcinomas |
Cytokeratin 5 |
|
CK5, CK 05, XM26, RCK103, 34BEH12 |
Adenoid Cystic Carcinoma; Atypical Ductal Hyperplasia; Basal-like Carcinomas; Ductal Carcinoma In Situ, Paget Disease; Epithelial Hyperplasia; Expression Profiling, Protein; Hereditary Cancer; Locally Recurrent Carcinoma; Metaplastic Carcinoma; Papilloma, Large Duct and Small Duct; Secretory Carcinoma |
Cytokeratin 5/6 |
|
CK5/6, CK 05_06, D5/16 B4 |
Papilloma, Large Duct and Small Duct; Basal-like Carcinomas |
Cytokeratin 7 |
|
CK7, CK 7, K72.7, KS7.18, OVTL 12/30, LDS-68, CK 07 |
Ductal Carcinoma In Situ, Paget Disease; Basal-like Carcinomas |
Cytokeratin 8 |
|
CK8, K8.8, 4.1.18, TS1, C-51, M20, CK 08, 35BH11, MA-902 |
Adenoid Cystic Carcinoma; Basal-like Carcinomas; Papilloma, Large Duct and Small Duct |
Cytokeratin 8/18 |
cytokeratin 8/18; simple epithelial-type cytokeratins |
5D3, Zym5.2, CAM 5.2, KER 10.11, NCL-5D3, cytokeratin LMW |
Basal-like Carcinomas; Papilloma, Large Duct and Small Duct |
Cytokeratin 14 |
high molecular weight cytokeratin |
CK14, LL002 |
Basal-like Carcinomas; Hereditary Cancer; Fibromatosis; Secretory Carcinoma |
Cytokeratin 17 |
|
E3, CK17 |
Basal-like Carcinomas |
Cytokeratin 18 |
|
CK18, M9, DC-10, CY-90, KS18.04 |
Ductal Carcinoma In Situ with Microinvasion |
Cytokeratin 19 |
low molecular weight cytokeratin |
CK19, BA17, RCK108, LP2K, B170, A53-BA2, KS19.1, 170.2.14 |
Circulating Tumor Cells |
D2-40 |
marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas |
Podoplanin, M2A |
Atypical Vascular Lesions of Skin; Lymph-Vascular Invasion |
Desmin |
class III intermediate filaments found in muscle cells |
M760, DE-R-11, D33, DE5, DE-U-10, ZC18 |
Diabetic Mastopathy/Lymphocytic Mastopathy; Fibromatosis; Granular Cell Tumor; Lipoma and Angiolipoma; Myofibroblastoma; Nodular Fasciitis; Sarcomas |
E-cadherin |
epithelial calcium dependent adhesion molecule |
36B5, ECH-6, ECCD-2, CDH1, 5H9, NCH 38, CLONE 36, 4A2 C7, E9, 67A4, HECD-1, SC-8426 |
Anatomic Structure and Lifecycle Changes; Invasive Apocrine Carcinoma; Atypical Ductal Hyperplasia; Atypical Lobular Hyperplasia; Collagenous Spherulosis; Ductal Carcinoma In Situ; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Epithelial Hyperplasia; HER2 Positive Carcinoma; Hereditary Cancer; Invasive Lobular Carcinoma Variants; Invasive Lobular Carcinoma; Invasive Micropapillary Carcinoma; Lobular Carcinoma In Situ; Medullary Carcinoma; Metaplastic Carcinoma; Metastases to the Breast; Neuroendocrine/Small Cell Carcinoma; Risk Factors for Developing Breast Carcinoma; Sclerosing Adenosis; Secretory Carcinoma; Tubulolobular Carcinoma |
EGFR |
v-erb-b1 erythroblastic leukemia viral gene,epidermal growth factor receptor |
2-18C9, EGFR1, EGFR PHRMDX, NCL-R1, H11, C-ERBB-1, E30, EGFR, EGFR.113, 31G7, 3C6, HER1, ERBB1, c-erb-B1 |
Invasive Apocrine Carcinoma; Basal-like Carcinomas; Expression Profiling, mRNA; Expression Profiling, Protein; HER2; Hereditary Cancer; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Locally Recurrent Carcinoma; Low-Grade Adenosquamous Carcinoma; Metaplastic Carcinoma; Mucinous (Colloid) Carcinoma; Secretory Carcinoma |
EMA |
epithelial membrane antigen |
GP1.4, 214D4, MC5, E29 |
Ductal Carcinoma In Situ, Paget Disease; Implant Pathology; Invasive Micropapillary Carcinoma; Lymphoma; Tubular/Cribriform Carcinoma |
Epidermal growth factor |
v-erb-b1 erythroblastic leukemia viral gene,epidermal growth factor receptor |
2-18C9, EGFR1, EGFR PHRMDX, NCL-R1, H11, C-ERBB-1, E30, EGFR, EGFR.113, 31G7, 3C6, HER1, ERBB1, c-erb-B1 |
Medullary Carcinoma |
Epithelial membrane antigen |
|
EMA, GP1.4, 214D4, MC5, E29 |
Lymph Node Metastases; Microglandular Adenosis |
ER |
estrogen receptor protein |
1D5, 6F11, SP1, 15D, H222, TE111, ERP, ER1D5, NCLER611, NCL-ERLH2, PGP-1A6 |
Adenoid Cystic Carcinoma; Anatomic Structure and Lifecycle Changes; Invasive Apocrine Carcinoma; Atypical Ductal Hyperplasia; Atypical Lobular Hyperplasia; Basal-like Carcinomas; Carcinomas with Extensive Intraductal Component; Checklist for the Reporting of Invasive Breast Carcinoma; Core Needle Biopsies; Ductal Carcinoma In Situ with Microinvasion; Ductal Carcinoma In Situ; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Epithelial Hyperplasia; Expression Profiling, Mammaprint Assay; Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay; Expression Profiling, Protein; Fibromatosis; General Considerations; Gynecomastia; Hamartoma (Fibroadenolipoma); HER2 Positive Carcinoma; HER2; Histologic Grade; Hormone Receptors (ER/PR); Inflammatory Carcinoma; Introduction: Prognostic and Predictive Factors; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Lobular Carcinoma Variants; Invasive Lobular Carcinoma; Invasive Micropapillary Carcinoma; Invasive Papillary Carcinoma; Lobular Carcinoma In Situ; Locally Recurrent Carcinoma; Lymph Node Metastases; Lymphoma; Medullary Carcinoma; Metaplastic Carcinoma; Metastases to the Breast; Mucinous (Colloid) Carcinoma; Myofibroblastoma; Neoadjuvant Therapy; Neuroendocrine/Small Cell Carcinoma; Risk Factors for Developing Breast Carcinoma; Sclerosing Adenosis; Secretory Carcinoma; Size and Multiple Foci; Syringomatous Adenoma of the Nipple; Tubular/Cribriform Carcinoma; Tubulolobular Carcinoma |
ER-α |
estrogen receptor protein α |
ER-ALPHA, ERP-α |
Anatomic Structure and Lifecycle Changes; Apocrine Carcinoma; Hormone Receptors (ER/PR) |
ER-β |
estrogen receptor protein β |
ER-BETA, 14C8, 57/3, PPG5/10 |
Apocrine Carcinoma; Hormone Receptors (ER/PR) |
ERP |
estrogen receptor protein |
1D5, 6F11, SP1, 15D, H222, TE111, ER, ER1D5, NCLER611, NCL-ERLH2, PGP-1A6 |
Anatomic Structure and Lifecycle Changes; Atypical Ductal Hyperplasia; Ductal Carcinoma In Situ, Paget Disease; Ductal Carcinoma In Situ; Expression Profiling, Protein; Hormone Receptors (ER/PR); Introduction: Prognostic and Predictive Factors; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Lobular Carcinoma; Invasive Micropapillary Carcinoma; Lobular Carcinoma In Situ; Microglandular Adenosis; Mucinous (Colloid) Carcinoma; Myofibroblastoma; Neoadjuvant Therapy; Neuroendocrine/Small Cell Carcinoma; Risk Factors for Developing Breast Carcinoma; Secretory Carcinoma; Syringomatous Adenoma of the Nipple; Tubular/Cribriform Carcinoma |
ERP-α |
estrogen receptor protein α |
ER-ALPHA, ERP-α |
Ductal Carcinoma In Situ, Paget Disease; Expression Profiling, mRNA; Hormone Receptors (ER/PR) |
Fascin |
marker for Reed-Sternberg cells of Hodgkin disease |
55K2 |
Basal-like Carcinomas |
GCDFP-15 |
gross cystic fluid protein 15 |
SABP, GPIP4, Gp17, 23A3, BRST-2, D6 (GROSS CYSTIC DISEASE FLUID PROTEIN) |
Encapsulated Papillary Carcinoma; Invasive Apocrine Carcinoma; Invasive Lobular Carcinoma Variants; Invasive Lobular Carcinoma; Lobular Carcinoma In Situ; Nonproliferative Changes; Papilloma, Large Duct and Small Duct; Secretory Carcinoma |
GH |
growth hormone |
HGH, hGH |
Ductal Carcinoma In Situ; Gynecomastoid Hyperplasia; HER2; Fibroadenoma |
Hep-Par1 |
hepatocyte paraffin 1 |
OCH1E5.2.10, HEPPAR1 |
Invasive Lobular Carcinoma |
HER2 |
v-erb-b2 erythroblastic leukemia viral gene protein, human epidermal growth factor receptor 2 |
c-erb-B2, HER2/neu, NEU, HER-2, NCL-CBE1, 10A7, 9G6.10, SP3, 4B5, Epidermal Growth Factor Receptor 2, P185, 9G6.20, A0485, C-ERBB-2, CB11, ERBB-2, 3B5, TAB250, HERCEPTEST, E2-4001, HER-2_NEU |
Basal-like Carcinomas; Carcinomas with Extensive Intraductal Component; Checklist for the Reporting of Invasive Breast Carcinoma; Circulating Tumor Cells; Core Needle Biopsies; DNA Analysis; Ductal Carcinoma In Situ; Ductal Carcinoma In Situ with Microinvasion; Ductal Carcinoma In Situ, Paget Disease; Encapsulated Papillary Carcinoma; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Expression Profiling, Mammaprint Assay; Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay; Expression Profiling, Protein; General Considerations; Hamartoma (Fibroadenolipoma); HER2; HER2 Positive Carcinoma; Hereditary Cancer; Histologic Grade; Hormone Receptors (ER/PR); Inflammatory Carcinoma; Introduction: Prognostic and Predictive Factors; Invasive Apocrine Carcinoma; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Lobular Carcinoma; Invasive Lobular Carcinoma Variants; Invasive Micropapillary Carcinoma; Invasive Papillary Carcinoma; Lobular Carcinoma In Situ; Locally Recurrent Carcinoma; Low-Grade Adenosquamous Carcinoma; Lymph Node Metastases; Margins and Reexcisions; Medullary Carcinoma; Metaplastic Carcinoma; Metastases to the Breast; Mucinous (Colloid) Carcinoma; Neoadjuvant Therapy; Neuroendocrine/Small Cell Carcinoma; Nipple Adenoma; Nonproliferative Changes; Secretory Carcinoma; Size and Multiple Foci; Tubular/Cribriform Carcinoma; Tubulolobular Carcinoma |
HER-2_NEU |
v-erb-b2 erythroblastic leukemia viral gene protein, human epidermal growth factor receptor 2 |
c-erb-B2, HER2/neu, NEU, HER-2, NCL-CBE1, 10A7, 9G6.10, SP3, 4B5, epidermal growth factor receptor 2, P185, 9G6.20, A0485, C-ERBB-2, CB11, ERBB-2, 3B5, TAB250, HERCEPTEST, E2-4001, HER-2_NEU |
HER2 |
HER3 |
v-erb-b3 erythroblastic leukemia viral gene protein, human epidermal growth factor receptor 3 |
HER-3 AB-8, ERBB3, C-ERBBB-3 |
HER2 |
HER4 |
v-erb-4 erythroblastic leukemia viral gene protein, human epidermal growth factor receptor 4 |
HFR-1, ERBB-4, HER-4 AB-4 |
HER2 |
HMB-45 |
antigen present in melanocytic tumors such as melanomas |
LB39 AA, CMM1, CMM, DNS, FAMMM, Mart1, Melan-A, MLM, tyrosinase |
Ductal Carcinoma In Situ, Paget Disease; Granular Cell Tumor |
IgG |
immunoglobulin G |
IGG |
Lymphoma |
Ki-67 |
marker of cell proliferation |
MMI, KI88, IVAK-2, MIB1 |
Anatomic Structure and Lifecycle Changes; Basal-like Carcinomas; Ductal Carcinoma In Situ, Paget Disease; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Epithelial Hyperplasia; Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay; Expression Profiling, Protein; Fibroadenoma; Hemangiomas; HER2 Positive Carcinoma; Hereditary Cancer; Histologic Grade; Introduction: Prognostic and Predictive Factors; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Lymph-Vascular Invasion; Phyllodes Tumor; Sclerosing Adenosis; Tubular/Cribriform Carcinoma; Expression Profiling, Protein; Histologic Grade; Introduction: Prognostic and Predictive Factors; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type) |
Laminin |
major protein in basal lamina |
LAMININ-4C7, 4C12.8, LAM-89 |
Adenoid Cystic Carcinoma; Anatomic Structure and Lifecycle Changes; Collagenous Spherulosis; Ductal Carcinoma In Situ with Microinvasion; Microglandular Adenosis |
Mammaglobin |
breast tissue-specific glycoprotein |
304-1A5 |
Anatomic Structure and Lifecycle Changes; Circulating Tumor Cells; Introduction: Prognostic and Predictive Factors; Invasive Micropapillary Carcinoma |
Mart-1 |
mart-1 clone of Melan A |
|
Ductal Carcinoma In Situ, Paget Disease |
Melan-A |
melanoma antigen recognized by T cells 1 (MART-1); protein found on melanocytes; melanocyte differentiation antigen |
M2-7C10, CK-MM |
Ductal Carcinoma In Situ, Paget Disease |
Melan-A-103 |
clone of Melan-A |
A103 |
Ductal Carcinoma In Situ, Paget Disease |
MNF 116 |
cytokeratin-pan (AE1/AE3/LP34); cocktail of high and low molecular weight cytokeratins |
keratin pan, MAK-6, K576, LU-5, KL-1, KC-8, MNF 116, pankeratin, pancytokeratin |
Metaplastic Carcinoma |
MUC1 |
epithelial membrane antigen |
LICR-LON-M8, BC3, DF3, VU3D1, MUSEII, RD-1, MA695, MA552, PS2P446, 115D8 |
Circulating Tumor Cells; Invasive Lobular Carcinoma; Invasive Micropapillary Carcinoma; Mucinous (Colloid) Carcinoma |
MUC2 |
mucin 1, intestinal |
CCP58, MUC2-P, M53, MRP, LUM2-3, LDQ10 |
Mucinous (Colloid) Carcinoma; Mucocele-like Lesions |
MUC5AC |
mucin 5AC, tracheobronchial, gastric |
CLH2 2, 45M1, CLH2 |
Mucinous (Colloid) Carcinoma |
MUC6 |
mucin 6, gastric |
CLH5 |
Mucinous (Colloid) Carcinoma; Mucocele-like Lesions |
Myogenin |
myogenic factor 4; class C basic helixloophelix protein 3 |
F5D, MYF3, MYF4, LO26, bHLHc3, cb553, MYF4, MYOG |
Sarcomas |
Myoglobin |
iron and oxygen-building protein found in muscle tissue |
MG-1 |
Granular Cell Tumor; Sarcomas |
Myosin |
motor proteins responsible for actin-based motility in striated and smooth muscle cells |
|
Adenoid Cystic Carcinoma; Collagenous Spherulosis; Ductal Carcinoma In Situ with Microinvasion; Pseudoangiomatous Stromal Hyperplasia; Sclerosing Adenosis |
NDRG1 |
n-myc downstream-regulated gene 1 |
|
Expression Profiling, Protein |
neuron specific enolase |
|
BSS/H14, NSE |
Granular Cell Tumor |
NTRK3 |
neurotrophic tyrosine kinase receptor 3 |
TRKC |
Secretory Carcinoma |
p21 |
cyclin dependent kinase inhibitor 1A |
WAF1, DCS-60.2, EA10, 6B6, 4D10, SX118, P21, P21_WAF1, WAFT |
Introduction: Prognostic and Predictive Factors |
p27 |
cyclin dependent kinase inhibitor 1B |
P27_KIP1, 57, 1B4, DCS-72.F6, SX53G8, P27, K25020, DCS72, KIP-1 |
Introduction: Prognostic and Predictive Factors |
p53 |
p53 tumor suppressor gene protein |
DO7, 21N, BP53-12-1, AB6, CM1, PAB1801, DO1, BP53-11, PAB240, RSP53, MU195, P53 |
Basal-like Carcinomas; DNA Analysis; Encapsulated Papillary Carcinoma; Epidemiology: Lesions Conferring Increased Risk of Breast Carcinoma; Expression Profiling, Protein; Hamartoma (Fibroadenolipoma); HER2 Positive Carcinoma; Hereditary Cancer; Inflammatory Carcinoma; Invasive Apocrine Carcinoma; Invasive Lobular Carcinoma Variants; Medullary Carcinoma; Metaplastic Carcinoma; Phyllodes Tumor |
p63 |
tumor protein p63 |
H-137, 7JUL |
Anatomic Structure and Lifecycle Changes; Atypical Lobular Hyperplasia; Basal-like Carcinomas; Collagenous Spherulosis; Ductal Carcinoma In Situ; Ductal Carcinoma In Situ with Microinvasion; Ductal Carcinoma In Situ, Paget Disease; Encapsulated Papillary Carcinoma; Fibromatosis; Hamartoma (Fibroadenolipoma); HER2; Iatrogenic Changes; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Papillary Carcinoma; Lobular Carcinoma In Situ; Locally Recurrent Carcinoma; Low-Grade Adenosquamous Carcinoma; Lymph-Vascular Invasion; Metaplastic Carcinoma; Microglandular Adenosis; Mucinous (Colloid) Carcinoma; Neuroendocrine/Small Cell Carcinoma; Nipple Adenoma; Nodular Fasciitis; Papilloma, Large Duct and Small Duct; Phyllodes Tumor; Radial Sclerosing Lesion/Radial Scar; Risk Factors for Developing Breast Carcinoma; Sarcomas; Sclerosing Adenosis; Secretory Carcinoma; Syringomatous Adenoma of the Nipple; Tubular/Cribriform Carcinoma |
p120 catenin |
cell adhesion molecule |
|
Invasive Lobular Carcinoma; Tubulolobular Carcinoma |
pax-8 |
paired box gene 8 |
PAX-8 |
Metastases to the Breast |
P-cadherin |
placental dependent adhesion protein |
56, clone 56 |
Anatomic Structure and Lifecycle Changes; Invasive Lobular Carcinoma; Metaplastic Carcinoma |
Podoplanin |
marker for reactive follicular dendritic cells and follicular dendritic cell sarcomas |
D2-40, M2A |
Anatomic Structure and Lifecycle Changes; Ductal Carcinoma In Situ; Inflammatory Carcinoma; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Locally Recurrent Carcinoma; Lymph-Vascular Invasion |
PR |
progesterone receptor protein |
10A9, PGR-1A6, KD68, PGR-ICA, PRP-P, PRP, PRI, 1A6, 1AR, HPRA3, PGR-636, 636, PR88, NCL-PGR |
Adenoid Cystic Carcinoma; Anatomic Structure and Lifecycle Changes; Basal-like Carcinomas; Checklist for the Reporting of Invasive Breast Carcinoma; Core Needle Biopsies; Ductal Carcinoma In Situ; Ductal Carcinoma In Situ with Microinvasion; Epithelial Hyperplasia; Expression Profiling, mRNA; Expression Profiling, Oncotype DX Assay; Expression Profiling, Protein; General Considerations; Gynecomastia; Hamartoma (Fibroadenolipoma); HER2; HER2 Positive Carcinoma; Histologic Grade; Hormone Receptors (ER/PR); Inflammatory Carcinoma; Introduction: Prognostic and Predictive Factors; Invasive Apocrine Carcinoma; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Lobular Carcinoma; Invasive Lobular Carcinoma Variants; Invasive Micropapillary Carcinoma; Lobular Carcinoma In Situ; Locally Recurrent Carcinoma; Lymph Node Metastases; Lymphoma; Margins and Reexcisions; Medullary Carcinoma; Metaplastic Carcinoma; Metastases to the Breast; Mucinous (Colloid) Carcinoma; Myofibroblastoma; Neoadjuvant Therapy; Neuroendocrine/Small Cell Carcinoma; Risk Factors for Developing Breast Carcinoma; Secretory Carcinoma; Size and Multiple Foci; Syringomatous Adenoma of the Nipple; Tubular/Cribriform Carcinoma; Tubulolobular Carcinoma |
Prostate specific antigen |
|
PSA, PSA-M, PSA, ER-PR8, PSA-P, F5 |
Gynecomastia |
Prostatic acid phosphatase |
|
PAP, PASE/4LJ, PAP-P |
Gynecomastia |
PRP |
progesterone receptor protein |
10A9, PGR-1A6, KD68, PGR-ICA, PRP-P, PRI, 1A6, 1AR, HPRA3, PGR-636, 636, PR88, NCL-PGR |
Hormone Receptors (ER/PR); Invasive Micropapillary Carcinoma Medullary Carcinoma |
PSAP |
|
|
Metastases to the Breast |
PTEN |
phosphatase and tensin homolog |
PN37 |
Hamartoma (Fibroadenolipoma); Hereditary Cancer; Invasive Apocrine Carcinoma; Risk Factors for Developing Breast Carcinoma |
S100 |
Low molecular weight protein normally present in cells derived from neural crest (Schwann cells, melanocytes, and glial cells), chondrocytes, adipocytes, myoepithelial cells, macrophages, Langerhans cells, dendritic cells, and keratinocytes |
S-100, A6, 15E2E2, Z311, 4C4.9 |
Ductal Carcinoma In Situ, Paget Disease; Fat Necrosis; Granular Cell Tumor; Hamartoma (Fibroadenolipoma); Iatrogenic Changes; Invasive Apocrine Carcinoma; Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Lobular Carcinoma Variants; Lymph Node Metastases; Metastases to the Breast; Microglandular Adenosis; Sarcomas; Secretory Carcinoma; Tubular/Cribriform Carcinoma; Sclerosing Adenosis |
SMHC |
myosin heavy chain smooth muscle |
ID8, SM_MYOSIN_H, HSM-V, SMMS-1 |
Anatomic Structure and Lifecycle Changes; Ductal Carcinoma In Situ with Microinvasion; Pseudoangiomatous Stromal Hyperplasia |
SP1 |
estrogen receptor protein |
1D5, 6F11, 15D, H222, TE111, ERP, ER1D5, NCLER611, NCL-ER-LH2 PGP-1A6 |
Hormone Receptors (ER/PR) |
SP3 |
v-erb-b2 erythroblastic leukemia viral gene protein, human epidermal growth factor receptor 2 |
c-erb-B2, HER2/neu, NEU, HER2, HER-2, NCL-CBE1, 10A7, 9G6.10, 4B5, Epidermal Growth Factor Receptor 2, P185, 9G6.20, A0485, C-ERBB-2, CB11, ERBB-2, 3B5, TAB250, HERCEPTEST, E2-4001, HER-2_NEU |
HER2 |
Survivin |
inhibitor of apoptosis |
AB469, SURVIVIN, FL-142, D8, 8E12 |
Expression Profiling, Oncotype DX Assay |
Synaptophysin |
major synaptic vesicle protein p38 antibody |
SVP38, SY38, SNP-88, SYP, SYPH, Sypl, Syn p38 |
Encapsulated Papillary Carcinoma; Invasive Papillary Carcinoma; Metastases to the Breast; Mucinous (Colloid) Carcinoma; Neuroendocrine/Small Cell Carcinoma |
TFE3 |
transcription factor E3 |
|
Granular Cell Tumor |
TTF-1 |
transcription termination factor |
8G7G3/1, SPT-24, SC-13040 |
Invasive Micropapillary Carcinoma; Metastases to the Breast; Neuroendocrine/Small Cell Carcinoma |
VEGF |
Vascular endothelial growth factor JH121, 26503.11, VPF, VPF/VEGF, VEGF-A, |
VEGF-C, RP 077, VEGFR-1, RP 076, VEGFR-2, 9D9, VEGFR-3, FLT-4 |
Basal-like Carcinomas; Inflammatory Carcinoma |
Vimentin |
major subunit protein of intermediate filaments of mesenchymal cells |
43BE8, 3B4, V10, V9, VIM-B34, VIM |
Granular Cell Tumor; Lipoma and Angiolipoma; Myofibroblastoma; Pseudoangiomatous Stromal Hyperplasia; Sarcomas |
WT1 |
Wilms tumor gene-1 |
6F-H2, C-19 |
Invasive Ductal Carcinoma (Adenocarcinomas of No Special Type); Invasive Micropapillary Carcinoma; Lymph Node Metastases; Metastases to the Breast |
|
